MGB Biopharma, a biopharmaceutical company developing a truly novel class of anti-infectives, has announced that it has successfully completed a topical formulation feasibility study with its lead antibacterial MGB-BP-3.
The preclinical study assessed two preliminary topical formulations of MGB-BP-3 in a skin infection model against a methicillin resistant Staphylococcus aureus (MRSA). The study showed that both formulations of MGB-BP-3 were successful in killing approximately 60% of the MRSA present.
These very promising findings pave the way for MGB Biopharma to begin a full topical formulation development programme for MGB-BP-3 with the goal of commercialising this novel antibacterial for a range of important skin infections.
Dr Miroslav Ravic, CEO of MGB Biopharma, said: “We are very pleased to be able to report that encouraging efficacy data has been obtained using MedPharm’s infected skin model against S. aureus, using non-optimized simple formulations and we are now looking at a number of options that will allow us to further optimise and develop this promising programme.”
MGB-BP-3 is a truly novel compound, based on minor groove binder (MGB) technology developed by the scientists from the University of Strathclyde. It represents a new class of drugs with a new mechanism of action that could transform the treatment of common, and potentially fatal, infectious diseases. In addition to medicines against Gram-positive pathogens, the MGB-based anti-infective platform has the potential to deliver drugs against multi-resistant Gram-negative pathogens, viruses, fungi and parasites.